Bristol-Myers Squibb Company





Market Closed - Nyse 04:00:01 2024-02-20 pm EST 5-day change 1st Jan Change
49.86 USD 0.00% Intraday chart for Bristol-Myers Squibb Company +2.36% -2.83%
This article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Aurora Cannabis Names Simona King CFO; Completes Share Consolidation MT
Bristol Myers: priority review in colorectal cancer CF
Bristol Myers Gets Priority FDA Review of Expanded Krazati Use DJ
Pfizer inflammatory bowel disease drug wins EU approval RE
Bristol-Myers Squibb Company Announces Management Changes CI
Bristol Myers: does not approve Tutanota offer CF
Kidney drug developer Aurinia fails to clinch a sale, sources say RE
Bristol Myers Squibb Reportedly Eyeing $13 Billion from Bond Sale Launched Wednesday MT
Bristol-Myers Squibb Gets FDA Priority Review for Repotrectinib to Treat Solid Tumors MT
Bristol Myers Gets Speedy FDA Review of Expanded Augtyro Use DJ
Bristol Myers: priority review accepted for Augtyro CF
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Augtyro (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors CI
VantAI Enters Collaboration with Bristol Myers Squibb to Accelerate Molecular Glue Drug Discovery Through Artificial Intelligence CI
Bristol-Myers Squibb, RayzeBio Say Hart-Scott-Rodino Act Waiting Period Expires MT
Bristol Myers: HSR period expires for RayzeBio CF
India's Zydus Lifesciences beats Q3 profit estimates; approves shares buyback RE
US Senate Democrats grill pharma CEOs on drug prices RE
Bristol-Myers Squibb Says US, EU Regulators Accept Filings for Opdivo to Treat Lung Cancer MT
Bristol Myers: FDA to review Opdivo in lung cancer CF
Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Neoadjuvant Opdivo and Chemotherapy Followed by Surgery and Adjuvant Opdivo in Resectable Non-Small Cell Lung Cancer CI
North American Morning Briefing : Stock Futures -2- DJ
Wells Fargo Adjusts Price Target on Bristol-Myers Squibb to $51 From $58, Maintains Equalweight Rating MT
Redburn Downgrades Bristol-Myers Squibb to Neutral From Buy, Adjusts Price Target to $54 From $77 MT
That's good enough for investors Our Logo
ANALYST RECOMMENDATIONS : Chevron, McDonald's, Palantir, Sainsbury, Tesla... Our Logo
  1. Stock
  2. Equities
  3. Stock Bristol-Myers Squibb Company - Nyse
  4. News Bristol-Myers Squibb Company
  5. Bristol-Myers Squibb Raises Quarterly Dividend to $0.60 a Share from $0.57, Payable on Feb. 1 to Shareholders as of Jan. 5
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance